EUVIMEDEUVIMED entdecken
Crossref

Tigecycline Usage for Severe Infections in the Pediatric Intensive Care Unit

İrem Ersayoğlu, Pınar Yazıcı Özkaya, Gizem Güner Özenen, Kübra Cebeci, Hatice Feray Arı, Zümrüt Şahbudak Bal, Sabire Şöhret Aydemir, Bülent Karapınar

Journal of Pediatric Infectious Diseases · 01.09.2024 · 19 (05) · 260-266

DOI: 10.1055/s-0044-1788342 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Infectious Diseases, erschienen am 01.09.2024. Verfasst von İrem Ersayoğlu und 7 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the effectiveness and safety of using tigecycline as a salvage therapy in critically ill children who did not respond to other antibiotics.

Methods

We conducted a retrospective cohort analysis that included children who received tigecycline for at least 48 hours and four doses during their pediatric intensive care unit admission. Demographic and clinical features of the subjects were evaluated through a comprehensive review of medical records. The effectiveness of tigecycline was assessed by thoroughly evaluating clinical and microbiological outcomes.

Results

During the study period, 72 pediatric patients with 88 episodes of infection received tigecycline according to antimicrobial susceptibility in 62.5% of cases and empirically in 37.5%. The median duration of tigecycline therapy was 10 days (range, 2–33 days). Klebsiella pneumoniae (n = 17, 30.9%) was the most frequently isolated pathogen, followed by Acinetobacter baumannii (n = 10, 18.1%). Ventilator-associated pneumonia was the most common infection (n = 29). Of the 55 isolated pathogens, 43 were multidrug-resistant (MDR), and 2 were extensively drug-resistant (XDR) gram-negative bacteria. Clinical response and microbiological clearance were achieved in 42 and 50.9% of episodes, respectively. The overall mortality was 40.9%, with an attributable mortality rate of 29.5%.

Conclusion

Tigecycline could be used as a salvage therapy for critically ill pediatric patients infected with MDR or XDR pathogens in the lack of alternative treatment options.

Zitieren

APA

Ersayoğlu, İ., Özkaya, P. Y., Özenen, G. G., Cebeci, K., Arı, H. F., Bal, Z. Ş., Aydemir, S. Ş., & Karapınar, B. (2024). Tigecycline Usage for Severe Infections in the Pediatric Intensive Care Unit. Journal of Pediatric Infectious Diseases, 19(05), 260-266. https://doi.org/10.1055/s-0044-1788342

Vancouver

Ersayoğlu İ, Özkaya PY, Özenen GG, Cebeci K, Arı HF, Bal ZŞ, et al. Tigecycline Usage for Severe Infections in the Pediatric Intensive Care Unit. Journal of Pediatric Infectious Diseases. 2024;19(05):260-266. doi:10.1055/s-0044-1788342

BibTeX
@article{Ersayolu2024,
  author = {Ersayoğlu, İrem and Özkaya, Pınar Yazıcı and Özenen, Gizem Güner and Cebeci, Kübra and Arı, Hatice Feray and Bal, Zümrüt Şahbudak and Aydemir, Sabire Şöhret and Karapınar, Bülent},
  title = {Tigecycline Usage for Severe Infections in the Pediatric Intensive Care Unit},
  journal = {Journal of Pediatric Infectious Diseases},
  year = {2024},
  volume = {19},
  number = {05},
  pages = {260--266},
  doi = {10.1055/s-0044-1788342}
}
Kostenlos starten →